Evidence map›Paper›PMID 30406944›Full record

Trial reportBritish journal of haematology2019

A phase II trial of eltrombopag for patients with chronic lymphocytic leukaemia (CLL) and thrombocytopenia.

Shilpa Paul, Nitin Jain, Alessandra Ferrajoli, Susan O'Brien, Jan Burger, Michael Keating, William Wierda

Abstract readClinical Trial, Phase IILetterMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of haematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shilpa PaulDivision of Pharmacy, the University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Nitin JainDepartment of Leukemia, the University of Texas, MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-0114-8384
Alessandra FerrajoliDepartment of Leukemia, the University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Susan O'BrienChao Family Comprehensive Cancer Center, University of California, Irvine Medical Center, Orange, CA, USA.
Jan BurgerDepartment of Leukemia, the University of Texas, MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-6177-7572
Michael KeatingDepartment of Leukemia, the University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
William WierdaDepartment of Leukemia, the University of Texas, MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-7357-270X

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Kathrin Milbury · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AgedAged, 80 and overBenzoatesFemaleHumansHydrazinesLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedPyrazolesThrombocytopeniaBenzoateseltrombopagHydrazinesPyrazolesCLLthrombocytopeniathrombopoietin

Identifiers

PMID30406944
PMCPMC11770971

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.